Several studies have demonstrated that monitoring of minimal residual disease (MRD) in childhood and adult acute lymphoblastic leukemia (ALL) significantly correlates with clinical outcome. MRD detection is particularly useful for evaluation of early treatment response and consequently for improved front-line therapy stratification. MRD information is also significant for children undergoing allogeneic hematopoietic stem cell transplantation and those with relapsed ALL. Currently, three highly specific and sensitive methodologies for MRD detection are available, namely multiparameter flow cytometric immunophenotyping, real-time quantitative polymerase chain reaction (RQ-PCR)-based detection of fusion gene transcripts or breakpoints, and RQ-PCR-based detection of clonal immunoglobulin and T-cell receptor gene rearrangements. In this review, characteristics, pitfalls, advantages and disadvantages of each MRD technique are critically discussed. The special emphasis is put on interlaboratory standardization, especially in view of the results obtained within the European collaborative BIOMED-1, BIOMED-2, and Europe Against Cancer projects and recent developments by European Study Group on MRD detection in ALL and EuroFlow Consortium. Standardized MRD techniques form the basis for stratification of patients into the risk groups in new treatment protocols mainly in childhood ALL. Only the results of these studies can answer the question whether MRD-based treatment intervention is associated with improved outcome. Leukemia ( The rationale for detection of MRD in ALL The concept of minimal residual disease (MRD) detection in acute lymphoblastic leukemias (ALL) is inherently associated with the progress in treatment of these malignancies.
The rationale for detection of MRD in ALL
The concept of minimal residual disease (MRD) detection in acute lymphoblastic leukemias (ALL) is inherently associated with the progress in treatment of these malignancies. 1 More than 80% of childhood and 35% of adult ALL patients can be cured with modern chemotherapy supplemented with hematopoietic stem cell transplantation (HSCT) in high risk patients (reviewed by Hoelzer et al. 2 ). Still, a substantial number of ALL patients relapse and the prediction of relapse with conventional prognostic factors such as age, blast count at diagnosis, immunophenotype at diagnosis, presence of chromosome aberrations, response to steroid prophase and classical clinical risk group assignment is far from optimal. Also microarray-based gene expression profiling could not identify gene signatures, typically associated with high risk of relapse. Tracing residual leukemic cells during early phases of treatment provides prognostic information superior to all known classical prognostic factors. Several prospective studies in childhood ALL demonstrated that the most relevant information comes from detection of MRD in bone marrow at the early phases of treatment, particularly at the end of induction treatment (reviewed by Szczepań ski et al. 3 and Cazzaniga and Biondi 4 ). Children with undetectable MRD at the end of induction have an excellent prognosis and are good candidates for treatment de-intensification or at least should not be subjected to further treatment intensification, particularly not to HSCT. [5] [6] [7] [8] [9] In childhood ALL, a group of ultrafast responders could be identified with successful clearance of MRD in bone marrow even within first 2 weeks of the induction. 10, 11 In contrast, children with high MRD levels at the end of induction treatment are in urgent need for treatment intensification or even for novel treatment approaches, particularly when such high MRD levels persist into the consolidation treatment. [5] [6] [7] [8] [9] Children with high-risk primary ALL and children with relapsed ALL planned for allogeneic HSCT can also profit from MRD monitoring. [12] [13] [14] [15] [16] [17] It is now generally accepted that one of the prerequisites for successful allo-HSCT is maximal reduction of MRD before start of the transplant procedure. Patients with high pretransplant MRD levels are at very high risk for ALL relapse. 12, 14, 15 Currently, the ongoing studies aim at assessment of possible approaches to lower pretransplant MRD levels and/or attune graft-versus-host reaction according to post-transplant MRD levels by modifying the immunosuppression to improve the outcome after HSCT. Finally, it was recently demonstrated that treatment stratification of standard risk adult ALL patients can be substantially improved when including MRD information. 18 In conclusion, based on the above-summarized significant results, several prospective treatment protocols, mainly in childhood ALL have been initiated including MRD-based treatment intervention as an essential part. Only the results of these studies can answer the question whether MRD-based treatment intervention is associated with improved outcome.
The methods for quantification of MRD in ALL
Optimal MRD techniques should be characterized by patient specificity (or at least leukemia specificity), satisfactory sensitivity (at least 10 À4 , i.e., one malignant cell among 10 000 normal cells), applicability for the vast majority of patients under the study, feasibility (easy standardization and rapid collection of results for clinical application) as well as intralaboratory and interlaboratory reproducibility. Another prerequisite for reliable MRD technique is precise quantification of MRD levels. The stringent criteria described above are for the greater part met by three approaches, namely multiparameter flow cytometric immunophenotyping, real-time quantitative polymerase chain reaction (RQ-PCR)-based detection of fusion gene transcripts or breakpoints, and RQ-PCR-based detection of clonal immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements (Table 1) . [19] [20] [21] Quantification with multiparameter flow cytometric immunophenotyping Precise quantification is an inherent feature of flow cytometry, which measures single cells. Up till now, immunophenotypic MRD detection in ALL was based on 3-4 color flow cytometry. This methodology relies on tracing the leukemia-specific immunophenotypes as the result of cross-lineage antigen expression, maturational asynchronous expression of antigens, antigen overexpression, absence of antigen expression, ectopic antigen expression, and various combinations of above-mentioned features bringing the ALL blasts into the 'empty spaces' between normal lymphoid differentiation (summarized by Campana 19 and Szczepań ski et al.
). Still the detection limit of this technique is not lower than 10
À3 -10
À4
, which nevertheless should be sufficient for identifying high-risk ALL patients. Another pitfall of flow cytometry is the modulation of antigen expression occurring during the treatment, which can change the leukemia-specific immunophenotype into a phenotype that resembles that of normal lymphoid precursors. 22, 23 Moreover, immunophenotypic changes might occur between diagnosis and relapse. 24 Therefore, following of at least two leukemiaspecific immunophenotypes per patient has been recommended to prevent false-negative results. It is striking that the most significant MRD studies in ALL employing flow cytometric immunophenotyping were based on a single expert laboratory. 7, 9 This raises the issue of interlaboratory standardization of flow cytometric reagents and procedures, which is essential for international multicenter treatment protocols. With the advent of bench top X6-color flow cytometers, higher sensitivity for MRD monitoring should be achieved, but with the increase of technical complexity the need for interlaboratory standardization becomes even more urgent. In Europe this need for innovation and standardization is supported by the European Commission via the EuroFlow Consortium aiming at standardization of 'Flow cytometry for fast and sensitive diagnosis and follow-up of hematological malignancies'. 25 
RQ-PCR-based quantification of leukemia-associated fusion genes
Leukemia-associated fusion genes resulting from chromosomal translocations are directly linked to leukemogenesis and therefore represent very good and stable disease-specific markers. After numerous single-center studies, the uniform primers and This mainly concerns del(1)(p32 p32) with SIL-TAL1 fusion and t(5;14) with aberrant HOX11L2 expression, together occurring in 25-35% of childhood T-ALL and in 15-20% of adult ALL (Graux 48 ).
Why and how to quantify MRD T Szczepański et al protocols for reverse transcription (RT)-PCR for identification of the most frequent fusion transcripts in ALL: t(1;19)(q23;p13) with the E2A-PBX1 fusion gene, t(4;11)(q21;q23) with the MLL-AF4 fusion gene, the two main types of t(9;22)(q34;q11) with BCR-ABL fusion genes, t(12;21)(p13;q22) with the TEL-AML1 fusion gene, and the intrachromosomal microdeletion on 1p32 with the SIL-TAL1 fusion gene, were standardized within the European BIOMED-1 and Europe Against Cancer networks. [26] [27] [28] However, these leukemia specific markers can be identified in not more than half of ALL patients, which limits their application as MRD markers for general cohorts of ALL patients. Still, several translocations are significant prognostic markers and identify 'homogenous' ALL subgroups. Both in childhood and adult ALL, t(9;22) with BCR-ABL fusion gene is associated with a dismal outcome, although rare cases with a very good sensitivity to chemotherapy could be also identified in this generally drugresistant subgroup of ALL. 29 With the addition of targeted treatment such as imatinib mesylate to current chemotherapy regimens for BCR-ABL þ ALL, BCR-ABL transcripts have become the first-choice marker for MRD monitoring by RT-RQ-PCR. 30, 31 In contrast, TEL-AML1 fusion gene occurring in approximately 25% of children with ALL identifies a subgroup with a very good prognosis for which the advantage of MRD monitoring is not yet fully proven.
The protocols for detection and quantification of fusion gene transcripts based on RT-RQ-PCR employing TaqMan technology have been developed thanks to European EAC network. 27 These MRD assays are characterized by reproducibly high sensitivity of 10 plasmid molecules or 10 À4 RNA cell line dilution for the majority of the targets. The EAC study also selected appropriate reference genes to correct variations in RNA quality and quantity and to calculate the sensitivity of each measurement. 28 These 'control' genes are characterized by highly stable expression in blood and bone marrow of normal and patient samples.
Because of the high sensitivity of PCR techniques, crosscontamination of RT-PCR products between patient samples is a major pitfall in RT-PCR-mediated MRD studies, resulting in up to 20% of false-positive results. 32 Such cross-contamination is difficult to recognize, as fusion gene transcripts, although leukemia-specific, are not patient-specific markers. Also the levels of fusion gene transcripts can vary significantly between patients. This is in contrast to PCR products obtained from genomic breakpoint fusions, which can be identified by use of patient-specific oligonucleotide probes in RQ-PCR assays. Unfortunately, in most translocations occurring in ALL the breakpoints are widely over multiple intronic sequences and their precise identification is rather complex. Nevertheless, the group of Marschalek was able to develop a single standardized approach to identify the vast majority of breakpoint fusions in the many different chromosome translocations involving the MLL gene on chromosome 11q23. The DNA breakpoints of MLL fusions were shown to be highly specific and sensitive RQ-PCR markers for MRD detection in MLL-rearranged infant and adult ALL. 33, 34 Such DNA-based approaches for precise breakpoint identification and MRD monitoring should ideally be developed for the other major ALL subgroups with specific chromosome translocations.
RQ-PCR-based quantification of junctional regions of Ig and TCR gene rearrangements
RQ-PCR-based detection and quantification of junctional regions of clonal Ig and TCR gene rearrangements is by far the most widely employed strategy of MRD monitoring in ALL.
Although this MRD strategy is the most laborious, expensive and time consuming, it is the most reproducible approach not only within the same laboratory but also between different laboratories. The junctional regions of clonal Ig and TCR gene rearrangements are fingerprint-like sequences for each lymphoid malignancy and can be identified in the vast majority of ALL patients using the standardized primer sets established through the European collaboration within the BIOMED-1 and -2 frameworks. [35] [36] [37] The immunobiologic studies identified and characterized oligoclonality and clonal evolution of Ig/TCR gene rearrangements between diagnosis and relapse. [38] [39] [40] [41] [42] Therefore, it is widely accepted that preferably at least two Ig/TCR targets should be followed per patient.
Although initial MRD studies employing different semiquantitative approaches, revealed significant results, 5, 8, 43 only the introduction of RQ-PCR was the major step towards the wider dissemination of this MRD strategy. 21, 44 À4 and 10 À5 , depending on the type of gene rearrangement and the size of junctional region. Another important guideline concerns the discrimination between low MRD positivity outside the quantitative range and false positivity resulting from nonspecific background amplification. Clearly, some Ig/TCR gene rearrangement junctions (particularly of TCRG), although unique for a particular patient, are so similar to rearrangements in the normal Ig/TCR repertoire that nonspecific amplification might occur from non-leukemic lymphocytes at low or even moderate levels. Therefore, the sensitivity of this MRD approach cannot easily be further improved. Realizing this, the studies demonstrating frequent MRD positivity in remission samples of children with ALL at the levels of 10 À7 should be interpreted with extreme caution. Finally, the report contains additional criteria for interpretation of RQ-PCR data, which take into account whether the clinical protocol aims at therapy intensification or treatment reduction. The conclusion that the ESG-MRD-ALL guidelines for interpretation of RQ-PCR MRD data enable uniform interpretation of MRD data between different MRD laboratories is therefore fully justified. 45 
Choice of MRD technique
The three major MRD techniques provide information expressed as seemingly identical MRD levels. Nevertheless, while flow cytometry relies on protein expression, fusion genes are generally detected at messenger RNA levels, and Ig/TCR junctions are RQ-PCR targets at the DNA level. As summarized in Table 1 , the three methodologies also differ in their sensitivity and applicability. Therefore, MRD data obtained with different techniques are hardly interchangeable. Small single-center studies claimed that results of MRD detection by flow cytometry and quantitative PCR of patient-specific Ig/TCR gene rearrangements are largely comparable. 46, 47 Indeed in 70-80% of samples with MRD levels 410 3 both techniques seem to give comparable results (p3-fold difference). However, in samples with MRD levels p10 3 , many discrepancies between the two techniques have been found; this hampers the recognition of low-risk patients. 46, 47 Consequently, usage of different MRD techniques for different patients within the same treatment protocol should be avoided.
What would be the future of MRD studies in ALL?
The story of MRD is one of the most exciting examples of translational research, where complicated basic research was transferred into high-technology laboratory diagnostics. It is beyond doubt that MRD diagnostics will be included in all ALL treatment protocols, as MRD data provide so far the most optimal reflection of the in vivo response to treatment, which gives the clinician a better knowledge and control of the clinical course in individual patients. It is fair to assume that such individualized medicine will finally translate into improved outcome of ALL patients. This is already obvious in case of high-risk ALL patients, particularly those undergoing allogeneic HSCT and still remains to be proved for general cohorts of patients. Introduction of novel, preferably targeted therapy will create additional applications of MRD monitoring. Still ongoing international collaborative efforts are necessary to ensure that all diagnostic MRD laboratories speak the same 'MRD language'.
